By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Nonsteroidal anti-inflammatory drugs > Esomeprazole and naproxen > Esomeprazole / Naproxen Dosage
Nonsteroidal anti-inflammatory drugs
https://themeditary.com/dosage-information/esomeprazole-naproxen-dosage-9162.html

Esomeprazole / Naproxen Dosage

Drug Detail:Esomeprazole and naproxen (Esomeprazole and naproxen [ ee-soe-mep-ra-zole-and-na-prox-en ])

Drug Class: Nonsteroidal anti-inflammatory drugs

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Ankylosing Spondylitis

One tablet (esomeprazole 20 mg-naproxen 375 mg or esomeprazole 20 mg-naproxen 500 mg) orally twice a day

Comments:

  • Not interchangeable with the individual components of naproxen and esomeprazole magnesium.

Uses: For the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing nonsteroidal anti-inflammatory drug (NSAID) associated gastric ulcers

Usual Adult Dose for Osteoarthritis

One tablet (esomeprazole 20 mg-naproxen 375 mg or esomeprazole 20 mg-naproxen 500 mg) orally twice a day

Comments:

  • Not interchangeable with the individual components of naproxen and esomeprazole magnesium.

Uses: For the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing nonsteroidal anti-inflammatory drug (NSAID) associated gastric ulcers

Usual Adult Dose for Rheumatoid Arthritis

One tablet (esomeprazole 20 mg-naproxen 375 mg or esomeprazole 20 mg-naproxen 500 mg) orally twice a day

Comments:

  • Not interchangeable with the individual components of naproxen and esomeprazole magnesium.

Uses: For the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing nonsteroidal anti-inflammatory drug (NSAID) associated gastric ulcers

Usual Pediatric Dose for Juvenile Idiopathic Arthritis

12 years or older:

  • At least 38 kg to less than 50 kg: One tablet (esomeprazole 20 mg-naproxen 375 mg) orally twice a day
  • Greater than 50 kg: One tablet (esomeprazole 20 mg-naproxen 375 mg or esomeprazole 20 mg-naproxen 500 mg) orally twice a day

Comments:
  • Not interchangeable with the individual components of naproxen and esomeprazole magnesium.

Use: For the relief of signs and symptoms of juvenile idiopathic arthritis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID associated gastric ulcers

Renal Dose Adjustments

Moderate to severe renal impairment (CrCl less than 30 mL/min): Not recommended

Liver Dose Adjustments

Mild to moderate liver impairment: Monitor closely and consider possible dose reduction based on the naproxen component
Severe hepatic impairment: Use should be avoided

Dose Adjustments

Elderly Patients:

  • Use caution when high doses are required; the lowest effective dose should be used due to an increased risk for adverse events and increased likelihood of concomitant renal or hepatic impairment and cardiac dysfunction.

Precautions

US BOXED WARNINGS: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.
  • This drug is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
  • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.

Safety and efficacy have not been established in patients younger than 12 years or less than 38 kg.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Take at least 30 minutes prior to a meal.
  • The tablet should be swallowed whole with liquid; do not split, chew, crush, or dissolve tablets.
  • If a dose is missed, it should be taken as soon as possible; however, if the next scheduled dose is due, do not take the missed dose and take the next dose on time; do not take 2 doses at one time.
  • Antacids may be used while taking this drug.

General:
  • The benefits versus risks ratio of esomeprazole-naproxen therapy should be assessed prior to commencing treatment and the lowest effective dose for the shortest duration possible employed.
  • This drug does not allow for a lower daily dose of esomeprazole; if a lower daily dose of 40 mg is appropriate, a different treatment should be considered.
  • Prior to commencing esomeprazole-naproxen, existing treatment with non-aspirin NSAIDs (including COX-2 selective inhibitors) and gastroprotective medications (such as proton pump inhibitors or H2 receptor antagonists) should be ceased.
  • Esomeprazole-naproxen is not recommended for initial treatment of acute pain.

Monitoring:
General: Regular surveillance is recommended in patients on long-term treatment, e.g., those treated for more than one year.
Cardiovascular: Blood pressure, myocardial infarction and stroke (particularly in patients with cardiovascular disease or cardiovascular risk factors)
Hematologic: Clinically significant bleeding from any source
Hepatic: Liver function tests, particularly ALT levels.
Renal: Renal function (serum creatinine and/or creatinine clearance)

Patient advice:
  • Patients should be cautioned against driving or operating machinery until they are reasonably certain that esomeprazole-naproxen will not adversely affect their ability to safely engage in such activities.
  • Patients should talk to their health care provider if they are pregnant, planning to become pregnant, or breastfeeding; NSAIDs should not be used at 20 weeks or later in pregnancy unless specifically advised to do so by their health care professional.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by